-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Here's Why We Think Porton Pharma Solutions (SZSE:300363) Is Well Worth Watching
Here's Why We Think Porton Pharma Solutions (SZSE:300363) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Porton Pharma Solutions (SZSE:300363). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Porton Pharma Solutions with the means to add long-term value to shareholders.
Check out our latest analysis for Porton Pharma Solutions
Porton Pharma Solutions' Improving Profits
Porton Pharma Solutions has undergone a massive growth in earnings per share over the last three years. So much so that this three year growth rate wouldn't be a fair assessment of the company's future. Thus, it makes sense to focus on more recent growth rates, instead. In impressive fashion, Porton Pharma Solutions' EPS grew from CN¥0.68 to CN¥1.50, over the previous 12 months. It's not often a company can achieve year-on-year growth of 121%. Shareholders will be hopeful that this is a sign of the company reaching an inflection point.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. The music to the ears of Porton Pharma Solutions shareholders is that EBIT margins have grown from 18% to 23% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.
In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.
SZSE:300363 Earnings and Revenue History August 14th 2022The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Porton Pharma Solutions' future EPS 100% free.
Are Porton Pharma Solutions Insiders Aligned With All Shareholders?
Since Porton Pharma Solutions has a market capitalisation of CN¥35b, we wouldn't expect insiders to hold a large percentage of shares. But we do take comfort from the fact that they are investors in the company. Notably, they have an enviable stake in the company, worth CN¥9.5b. This totals to 27% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. Very encouraging.
Should You Add Porton Pharma Solutions To Your Watchlist?
Porton Pharma Solutions' earnings per share growth have been climbing higher at an appreciable rate. This level of EPS growth does wonders for attracting investment, and the large insider investment in the company is just the cherry on top. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering Porton Pharma Solutions for a spot on your watchlist. However, before you get too excited we've discovered 1 warning sign for Porton Pharma Solutions that you should be aware of.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於初學者來説,收購一家向投資者講述一個好故事的公司似乎是一個好主意(也是一個令人興奮的前景),即使它目前沒有收入和利潤的記錄。但正如彼得·林奇在華爾街上的一位“遠投幾乎永遠不會有回報。”一家虧損的公司還沒有用盈利來證明自己,最終外部資本的流入可能會枯竭。
因此,如果這種高風險和高回報的想法不適合,你可能會對盈利的、成長型的公司更感興趣,比如波頓製藥解決方案(SZSE:300363)。即使這家公司得到了市場的公平估值,投資者也會同意,產生持續的利潤將繼續為Porton Pharma Solutions提供為股東增加長期價值的手段。
查看我們對Porton Pharma Solutions的最新分析
波頓製藥解決方案公司不斷提高的利潤
波頓製藥解決方案公司在過去三年中每股收益大幅增長。以至於這三年的增長率對公司的未來不是一個公平的評估。因此,關注更近期的增長率是有意義的。在過去的12個月裏,Porton Pharma Solutions的每股收益從0.68元增長到1.50元,令人印象深刻。一家公司能夠實現121%的同比增長並不常見。股東們將滿懷希望地認為,這是公司走到拐點的跡象。
仔細考慮收入增長和息税前利潤(EBIT)利潤率有助於瞭解最近利潤增長的可持續性。Porton Pharma Solutions股東聽到的消息是,在過去12個月中,息税前利潤從18%增長到23%,收入也呈上升趨勢。這兩個都是衡量潛在增長的很好的指標。
在下面的圖表中,你可以看到該公司如何隨着時間的推移實現了收益和收入的增長。要查看實際數字,請點擊圖表。
SZSE:300363收益和收益歷史2022年8月14日作為投資者,訣竅在於找到符合以下條件的公司要去在未來有好的表現,而不僅僅是在過去。雖然水晶球並不存在,但你可以查看我們對Porton Pharma Solutions未來每股收益100%免費的共識分析師預測的可視化。
波頓製藥解決方案的內部人員是否與所有股東保持一致?
由於Porton Pharma Solutions的市值為人民幣350億元,我們預計內部人士不會持有很大比例的股份。但我們確實感到欣慰的是,他們是該公司的投資者。值得注意的是,他們在該公司持有令人羨慕的股份,價值95億元人民幣。這相當於該公司27%的股份。足以引導管理層的決策過程走上為股東帶來最大利益的道路。非常鼓舞人心。
您是否應該將Porton Pharma Solutions添加到您的觀察名單中?
Porton Pharma Solutions的每股收益增長一直在以可觀的速度攀升。這種水平的每股收益增長在吸引投資方面創造了奇蹟,而對該公司的大量內部投資只是上面的櫻桃。當然,人們希望,強勁的增長標誌着商業經濟學的根本改善。因此,基於這一快速分析,我們確實認為值得考慮Porton Pharma Solutions在您的觀察名單上佔據一席之地。然而,在你過於興奮之前,我們已經發現波頓製藥解決方案的1個警告標誌這一點你應該知道。
總是有可能做得很好,購買股票不是不斷增長的收入和不要有內部人士購買股票。但對於那些考慮這些重要指標的人,我們建議您查看以下公司做擁有這些功能。你可以在這裏訪問它們的免費列表。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧